Molecular Formula | C12H8N4O6S |
Molar Mass | 336.28 |
Density | 1.6027 (rough estimate) |
Melting Point | 361°C |
Solubility | methanol: 0.25mg/mL |
Appearance | solid |
Color | yellow |
pKa | 7.55±0.20(Predicted) |
Storage Condition | Inert atmosphere,2-8°C |
Stability | Freezer at -20°C |
Refractive Index | 1.6000 (estimate) |
In vitro study | NBQX (FG9202) has a high affinity for AMPA and kainate binding sites with little or no affinity for the glutamate recognition site on the NMDA receptor complex. |
In vivo study | NBQX (FG9202; 20 mg/kg, i.p.; for 3 days) decreases seizures induced by PTZ. NBQX is neuroprotective in a focal ischaemia model in the rat when given as an i.v. bolus dose of 30 mg/kg at the time of MCA occlusion and again at 1 h post occlusion. Animal Model: Male Wistar rats that weighed 220-240 g with pentylenetetrazole (PTZ) Dosage: 20 mg/kg Administration: IP; for 3 days Result: Effectively reversed the behavioral abnormality of epileptic seizures of chronic PTZ administration (50mg/kg; i.p.; for 28 days) in rats. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
biological activity | NBQX (FG9202, NNC 079202) is a competitive antagonist of AMPA receptor (AMPAR) with high selectivity and has anti-epileptic effect. |
target | TargetValue AMPAR () |
Target | Value |
in vitro study | NBQX (FG9202) has a high affinity for AMPA and kainate binding sites with little or no affinity for the glutamate recognition site on the NMDA receptor complex. |
in vivo study | > NBQX (FG9202; 20 mg/kg, I. p.; For 3 days) decreases seizures induced by PTZ. NBQX is neuroprotective in a focus ischaemia model in the rat when given as an I. v. bolus dose of 30 mg/kg at the time of mca occlusion and again at 1 h post occlusion. Animal model: male wistar rat that weighed 220-240g with pentylenetetrazole (PTZ) Dosage: 20 mg/kg Administration: IP; For 3 days Result: Effectively reversed the behavioral abnormality of epileptic seizures of chronic PTZ administration (50 mg/kg; I. p.; For 28 days) in rats. |
Animal Model: | Male Wistar rats that weighed 220-240g with pentylenetetrazole (PTZ) |
Dosage: | 20 mg/kg |
Administration: | IP; for 3 days |
Result: | Effectively reversed the behavioral abnormality of epileptic seizures of chronic PTZ administration (50mg/kg; I .p.; for 28 days) in rats. |